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Abstracts / Osteoarthritis and Cartilage 20 (2012) S54–S296S76indicated that 10.5% (RMS t¼2.95, p¼0.002) of the tibial surface was ﬂatter
in cases when compared to controls with the medial tibia most affec-
ted(Figure 1). Adjusted ROC analysis indicated the average curvature at the
central medial femur had an AUC of 0.66, and the medial tibia had an AUC
of 0.62 (Table 1) with p-values for both lower than 0.001. The cMF Logistic
model predicted 70% of TKR cases with a false positive rate of
30%(AUC¼0.79).
ĂFigure 1: Statistical Parametric Mapping (SMP). a) TKR Cases Mean
curvature map. b) Controls Mean curvature map. d) Effect size
map: [mean difference]/[paired standard deviation]. d) Location of
statistically signiﬁcant differences in curvature adjusted for false
discovery (p<0.05).
ĂTable 1: ROI analysis of mean curvatures. Population means (Standard
deviations) are shown for TKR and Control groups. Paired differences are
shown as t-values. The unadjusted and adjusted AUC with corresponding
Wilcoxon signed rank test p-value is shown in the fourth and ﬁfth column.
The last column shows the AUC of an unconditional logistic model at T0
controlled for Gender, Age, BMI, Total WOMAC pain, KL grade and adjusted
curvature.
Conclusions: Knees undergoing TKR had ﬂatter central medial femoral
condyle and medial tibia compared to matched non-TKR knees. Bone
curvatures clearly differentiated case from control knees, predicting those
at greatest risk of requiring a TKR and indicating the potential clinical
validity of this endpoint in DMOAD trials.Predictor Range of
predictor
values
Proportion
of medial JSN
progression
OR for medial
JSN progression
Baseline M:L
paBMD
(0.58 - 1.03) lowest
quartile
4/116 (3.5%) Referent
(1.03 - 1.11) 9/112 (8.0%) 2.5 (0.7 - 8.3)
(1.11 - 1.20) 17/118 (14.4%) 4.8 (1.6 - 14.7)
(1.20 - 1.78) highest
quartile
26/114 (22.8%) 8.4 (2.8 - 25.0)
p for trend
< 0.0001
M:L paBMD
change
(per yr)
(-0.12 - -0.02) lowest
quartile
6/118 (5.1%) Referent
(-0.02 - 0) 7/118 (5.9%) 1.2 (0.4 - 3.7)
(0 - 0.02) 20/109 (18.4%) 4.3 (1.6 - 11.1)
(0.02 - 0.4) highest
quartile
23/115 (20.0%) 4.7 (1.9 - 12.1)
p for trend
< 0.0001140
PERIARTICULAR BONE DENSITY AND TRABECULAR MORPHOLOGY
PREDICT KNEE OA STRUCTURAL PROGRESSION
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Purpose: Processes in periarticular bone are prominent in OA and
may participate in the pathophysiology of knee OA progression. The
purpose of this study was to evaluate whether periarticular bone
mineral density (paBMD), measured by dual-energy x-ray absorpti-
ometry (DXA), and trabecular morphology, measured by magnetic
resonance (MR) imaging, are predictive of structural progression of
knee OA.Methods: In an ancillary study to the Osteoarthritis Initiative (OAI),
subjects were evaluated with knee DXAs and trabecular MR exams.
Plain knee X-rays were read for joint space narrowing (JSN) as part of
the parent study. Knee DXAs and trabecular MR exams were obtained
at the OAI 30 or 36 month and the 48 month visits. DXAs of the knee
provided medial:lateral periarticular bone mineral density (M:L
paBMD) measures. Using a customized program (calcDCN), the
following trabecular properties were measured: apparent bone
volume fraction (aBVF), trabecular number (aTr.N), trabecular thick-
ness (aTr.Th) and trabecular spacing (aTr.Sp). Weight-bearing PA ﬁxed
ﬂexion knee x-rays obtained at the OAI 24 and 48 month visits were
assessed for medial tibio-femoral joint space narrowing (JSN) (0-3)
according to the OARSI atlas. Worsening of medial JSN that occurred
between months 24 to 48 within a given OARSI atlas medial JSN grade
was also scored. We performed logistic regression with the outcome
being any worsening of medial JSN between OAI visits 24 and 48,
including within OARSI JSN grade worsening. The predictors of
interest included the 30 or 36 month M:L paBMD, aBVF, aTr.N,
aTr.Th, and aTr.Sp divided into quartiles. We also evaluated rate of
change in these variables from the 30 or 36 month visit to the 48
month visit divided into quartiles. We then repeated these analyses
restricting to those knees with medial JSN scores of 0 or 1 at the 24
month visit.
Results: 497 participants were included in the study with a mean age of
64 (SD 9.1) years, 53% were male, mean BMI was 29.6 (SD 4.8) kg/m2. At
the OAI 24 month visit, 223 had a medial tibio-femoral JSN score of 0, 131
with a score of 1, 99 with a score of 2, and 28 with a score of 3. Of the 56
knees that had JSN score worsening by 48 months, the OAI 24 month JSN
scores were 0 for 6 knees, 1 for 17 knees, and 2 for 33 knees. The main
results from the logistic regression analyses are in the table below where
greater baseline M:L paBMD, rate of change of M:L paBMD, baseline BVF
and rate of change of BVF were associated with greater progression of
medial JSN.
The trabecular morphometry results were similar for a.Tr.N, a.Tr.Th as they
were for aBVF and in the opposite direction for a.Tr.Sp. Results were similar
when restricting analyses only to knees that had a medial JSN score of 0 or
1 at the OAI 24 month visit.
Conclusions: Baseline and longitudinal change of periarticular bone
structure are highly predictive of knee OA structural progression, even in
knees with mild disease. Increased pa BMD likely indicates changes in
trabecular morphology including increased aBVF, aTr.N, aTr.Th, and
reduced aTr.Sp. Meaningful change in paBMD and trabecular morphom-
etry can be measured over one year. paBMD is a simple test and has the
potential to be useful in predicting knees at higher risk for progressive
medial joint space narrowing.
aBVF Predicts Knee OA Structural Progression
Predictor Range of
predictor
values
Proportion of
medial JSN
progression
OR for medial
JSN progression
Baseline aBVF (0.008 - 0.06) lowest quartile 12/121 (9.9%) Referent
(0.06 - 0.09) 11/117 (9.4%) 0.9 (0.4 - 2.2)
(0.09 - 0.13) 9/108 (8.3%) 0.8 (0.3 - 2.0)
(0.13 - 0.54) highest quartile 24/116 (20.7%) 2.4 (1.1 - 5.0)
p for trend ¼ 0.02
aBVF
change(per yr)
(-0.22 - -0.01) lowest quartile 7/112 (6.3%) Referent
(-0.01 - 0) 13/115 (11.3%) 2.0 (0.8 - 5.2)
(0 - 0.01) 12/114 (10.5%) 1.8 (0.7 - 4.9)
(0.01 - 0.18) highest quartile 24/116 (20.1%) 4.1 (1.7 - 10.0)
p for trend ¼ 0.002
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ARGS NEOEPITOPE, PRESUMABLY DERIVED FROM ADAMTS5 ACTIVITY,
IS ELEVATED IN SERUM AND URINE FROM OSTEOARTHRITIS PATIENTS
UNDERGOING KNEE REPLACEMENT
F.M. Germaschewski 1, L.R. Cooper 1, F. Liu 2, J. Larkin 2, S. Woodward 3,
A.-C. Bay-Jensen 4, M. Karsdall 4, C. Matheny 2. 1GlaxoSmithKline,
Stevenage, Herts, UNITED KINGDOM; 2GlaxoSmithKline, Philadelphia, PA;
3 Synarc, Paris, FRANCE; 4Nordic BioSci., Herlev, DENMARK
Purpose: Proteolytic degradation of aggrecan in articular cartilage is
a characteristic feature of osteoarthritis (OA). ADAMTS5-mediated
cleavage of aggrecan generates the 374ARGS neoepitope. The objective of
this study was to evaluate 374ARGS levels in variousmatrices from different
OA populations in contrast to human subjects and assess performance of
a sensitive target-speciﬁc immunoassay to facilitate the clinical develop-
ment of an ADAMTS5 inhibitor for the treatment of OA.
Methods:Matched sera and urine were collected from 20 healthy subjects
(13 women, 7 men) aged from 26 to 60 years (mean  SD: 43.28.4) and
from 20 subjects with knee OA (12women, 8 men aged from 49 to 77 years
(meanSD: 66.1 7.36). Matched serum, urine and synovial ﬂuid was
obtained from 19 subjects undergoing joint replacement for knee OA (15
women, 9 men) aged from 47 to 85 years (meanSD: 69.111.30). Diurnal
and inter-day variation (over 3 visits) was evaluated in the non-surgical OA
group. Serum and urine samples were collected on two visits for the
patients undergoing knee replacement with synovial ﬂuid taken only at
the time of surgery. Correlation to additional biomarkers including OSM,
COMP, PIIANP, CTX-II, CTX-1, OC, hsCRP, CPII, CIIM, AGNx-1 was assessed.
ARGS neoepitope was quantitated using a chemiluminescent Meso-Scale-
Discovery (MSD) immunoassaywhich had been optimised and validated in
serum, plasma, urine and synovial ﬂuid. In brief, a commercial anti-
aggrecan capture antibody was coupled with a sulfo TAG labelled GSK
antibody speciﬁc to the 374ARGS neoepitope (OA-1). 374ARGS standard was
generated by digestion of aggrecan with ADAMTS5 which was diluted in
appropriate matrices pre-depleted of 374ARGS. The lower limit of quanti-
ﬁcation was 1.37, 0.46, and 4.12 ng/mL in serum, urine, and synovial ﬂuid
respectively.
Results: The mean concentration of 374ARGS neoepitope in serum from
healthy subjects was 4.32.2ng/mL (range 0.9-8.9 ng/mL), 5.92.7ng/mL
(range 1.1-10.0) in non-surgical OA subjects, and 9.34.6ng/mL (range 2.0-
16.5) in the surgical OA patients. Synovial ﬂuid concentrations of 374ARGS
in the surgical OA patients were similar to serum levels in those patients
(meanSD: 8.285.29). 374ARGS levels were lower in urine than serum in
all subjects but showed a similar trend of elevation in the surgical OA
patients (meanSD 5.94.5 range 0.5-13.9) compared to 3.312.28
(meanSD) in non-surgical OA patients (range 0.5-8.7) and 2.73.3
(meanSD) in healthy subjects (range 0-10.8). Compared to healthy
subjects, both serum (p¼0.004) and urine levels (p¼0.008) of 374ARGS
were signiﬁcantly elevated in the surgical OA patients. No signiﬁcant
difference was seen between healthy and non-surgical OA subjects. No
signiﬁcant diurnal effect or inter-day variance was observed in urine or
serum. Serum levels of 374ARGS correlated positively with COMP and CTX-
II (p<0.05) but not with other markers (OSM, PIIANP, CTX-1, OC, hsCRP,
CPII, CIIM, AGNx-1).Conclusions: This study utilized a highly sensitive and robust assay to
provide an initial evaluation of 374ARGS neoepitope concentrations in
various matrices in OA patients and healthy volunteers. There was
a general trend for increasing 374ARGS neoepitope concentration in serum
going from healthy subjects to non-end stage knee OA patients to end
stage (knee replacement) knee OA. Additional studies are planned to
evaluate 374ARGS as a diagnostic tool to facilitate patient selection as well
as provide an early indication of the pharmacodynamic effects of an
ADAMTS5 inhibitor in clinical trials.
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GENES ASSOCIATED WITH OSTEOARTHRITIS IDENTIFIED BY
MICROARRAY-ANALYSIS OF WHOLE BLOOD SAMPLES LINK OA TO
APOPTOTIC PATHWAYS
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Purpose: Recently, genome wide association (GWA) studies have been
performed and the ﬁrst consistent OA-susceptibility loci have emerged.
Nevertheless, additional insight about the molecular and cellular aspects
of osteoarthritis (OA) is necessary. Gene expression proﬁling of peripheral
blood cells may be a valuable tool for assessing signatures of differential
gene expression related to disease. In the current study, an extensive large
scale exploration of gene expressionwas performed in mononuclear blood
cells of distinct osteoarthritis (OA) cases of the GARP study and their age-
and disease-matched controls.
Methods: We used a subset of 108 samples from the GARP-study which
consists of Dutch sibling pairs with symptomatic and radiographic OA in
two or more joint sites of the hand, spine (cervical or lumbar), knee or hip.
As comparison we included 33 age-matched controls without any radio-
graphic or symptomatic OA in the indicated joints. RNA was isolated
speciﬁcally of mononuclear blood cells after Histopaque separation.
Microarray analysis was performed on Illumina Human HT-12_v3_Bead-
Chips after conﬁrming integrity of the RNA with lab-on-a-chip. Pathway
analysis was performed with the Database for Annotation, Visualization
and Integrated Discovery (DAVID) tool.
Results: Data obtained in this study showed high quality expression
proﬁles. After normalization, adjusting for sex and age and correcting for
multiple testing we found 567 probes representing 528 genes that showed
signiﬁcant differential expression between cases and controls. From these,
81 probes (79 genes) show a difference of 1.5 times or more (lowest P-
value ¼ 8.2*10-13). When the latter group of genes was used for gene
enrichment analysis in DAVID (GO-terms all Biological Pathways (BP_all)),
apoptosis was identiﬁed as a highly signiﬁcant pathway (P-value¼5.4*10-
3) due to differential expression of 13 genes herein. Notable in this pathway
was the differential expression of the well known apoptotic gene CASP3
which has also been linked to cartilage degradation in OA.
Conclusions: In this study, we have determined a distinctive gene
expression signature of blood from OA patients in comparison to age and
diseased matched controls. Interestingly, in this signature, genes involved
